Jefferies analyst Brian Tanquilut downgraded Tenet Healthcare to Hold while raising his price target for the shares to $38 from $28. The stock is fairly valued after rallying 128% year-to-date, Tanquilut tells investors in a research note. He believes the shares, at 7.5 times fiscal 2019 EBITDA, adequately reflect Tenet's growth prospects. Meaningful upside is now mostly predicated on the monetization of Conifer at a valuation above 10 times EBITDA, the analyst contends. Further, Tanquilut thinks volume acceleration for hospitals is unlikely due to macro factors.